Dendritic cell vaccine - SBI Biotech

Drug Profile

Dendritic cell vaccine - SBI Biotech

Alternative Names: Immunocell Therapy Project - SBI Biotech

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator SBI Biotech
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma; Solid tumours

Most Recent Events

  • 24 Sep 2015 No recent reports of development identified - Phase-I/II for Malignant melanoma in Japan (SC)
  • 24 Sep 2015 No recent reports of development identified - Preclinical for Solid tumours in Japan (unspecified route)
  • 17 Aug 2012 SBI Biotech completes enrolment in its phase I/II trial for Malignant melanoma in Japan (UMIN000004617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top